PQ Bypass Earns Frost & Sullivan's European Technology Innovation Award for Its Proprietary DETOUR System for Percutaneous Bypass

USA - English

• USA - English

LONDON, Aug. 31, 2017 /PRNewswire/ -- Frost & Sullivan is pleased to recognize PQ Bypass with the 2017 European PAD Interventions Technology Innovation Award. PQ Bypass' DETOUR System is a minimally invasive technology that enables physicians to re-direct, or detour, blood flow around extremely long blockages in the upper leg arteries to restore blood flow to the lower leg and foot.

"PAD is a potentially fatal condition that affects more than 200 million people worldwide—3 to 12% of the global population. PQ Bypass' proprietary DETOUR System is a promising, innovative approach for patients with extremely long lesions whose current treatment options are not ideal," said Frost & Sullivan Best Practices Analyst, Norma Vela. "We anticipate rapid, widespread technology adoption once the DETOUR System launches commercially. The global market potential for treating this type of advanced peripheral arterial disease is significant, and PQ Bypass has first-mover status in the space."

Extremely long blockages in the leg arteries, especially those that are greater than 20 centimeters, are challenging to treat. Historically, physicians have treated these blockages with open bypass surgery (fem-pop bypass), which has the benefit of durability, however, it is associated with an increased risk of complications, longer hospital stays, and prolonged rehabilitation. More recently, minimally-invasive technologies have emerged that go through blockages. These technologies work very well on shorter blockages; however, they have not been as effective on these longer blockages as open surgery.

The DETOUR System is designed to deliver the durability advantages of open bypass surgery with a minimally-invasive approach. During a DETOUR procedure, a pathway is created by crossing from the SFA into the femoral vein and back into the artery that allows DETOUR stent grafts to be placed in a continuous line. The new path through the stent grafts re-directs oxygen-rich blood around the blockage and restores blood flow to the lower leg and foot of the patient.

"With an increased focus on value-based and patient-centered medicine, surgical advancements that minimize trauma to patients, reduce length of hospital stay and recovery times are critical global needs," said Richard Ferrari, Chairman of the Board of PQ Bypass. "We designed the DETOUR System to be a transformative step forward in how physicians treat extremely long peripheral artery disease."

In March 2017, PQ Bypass received CE Mark approval for the DETOUR System and is planning a pivotal investigational device exemption study to support premarket approval from the US Food and Drug Administration (FDA). The clinical results of the DETOUR I trial conducted in Europe were promising, demonstrating excellent safety and effectiveness with patency results of 84.7% at 6 months.

Each year, Frost & Sullivan presents this award to a company that has developed a pioneering technology that enhances current products and develops newer products and applications. The award recognizes the high market acceptance potential of the recipient's technology.

Frost & Sullivan Best Practices Awards acknowledge companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About PQ Bypass

PQ Bypass, Inc. is a Silicon Valley-based medical device company working to transform the treatment of long-segment peripheral artery disease with minimally-invasive endovascular solutions.

PQ Bypass is operated by recognized leaders in the medical device industry. Our executive team members have held senior leadership positions at companies including Medtronic, Abbott, Johnson & Johnson, and Stryker and also have extensive experience developing medical devices for startups such as Evalve, Access Closure, Avinger, and DVI.

The underlying technology and technique used in the percutaneous PQ DETOUR procedure were co-developed by two world-renowned cardiologists and innovators, Dr. James Joye and Dr. Richard Heuser, who are recognized experts in PAD.

The PQ Bypass technology platform is not available for sale in the US. For more information, please visit www.pqbypass.com.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, collaborates with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, Frost & Sullivan has been developing growth strategies for the global 1000, emerging businesses, the public sector, and the investment community. Contact us: Start the discussion.

SOURCE Frost & Sullivan

Related Links

http://www.frost.com